Sofinnova Ventures Inc
13F Reported Value
ⓘ$2.6B
incl. option notional
Equity Holdings
ⓘ$2.0B
Option Notional
ⓘ$635.2M
$595.0M puts / $40.2M calls
Holdings
74
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Sofinnova Ventures Inc disclosed 74 positions worth $2.6B in its Form 13F-HR for Q1 2026 — $2.0B in common stock plus $635.2M of put/call option positions (reported at underlying notional value, not premium at risk), led by $NTRA (Natera, Inc.) at 15.5% of the equity portfolio. During the quarter the fund opened 29 new positions and exited 15 and a full exit from $VRTX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Sofinnova Ventures Inc’s Form 13F-HR filing with the SEC under CIK 1631134.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 46.4#1,659
Quality
$310.0M1,550,280 sh iShares TR PUT
—Quality
$148.8M600,000 shSPDR Series Trust PUT
—Quality
$134.1M1,050,000 sh- 70.1
Quality
$120.6M1,988,721 sh - —
Quality
$113.1M598,327 sh - —
Quality
$112.4M2,793,987 sh - 80.1
Quality
$94.9M160,070 sh - —
Quality
$89.9M456,031 sh - $86.6M150,000 sh
- —
Quality
$81.4M2,113,551 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Natera, Inc.$NTRA | 46.4#1,659 | $310.0M | 1,550,280 |
| iShares TR PUT | — | $148.8M | 600,000 |
| SPDR Series Trust PUT | — | $134.1M | 1,050,000 |
 BRISTOL MYERS SQUIBB CO$BMY | 70.1 | $120.6M | 1,988,721 |
 Jazz Pharmaceuticals plc$JAZZ | — | $113.1M | 598,327 |
 Vera Therapeutics, Inc.$VERA | — | $112.4M | 2,793,987 |
 UNITED THERAPEUTICS Corp$UTHR | 80.1 | $94.9M | 160,070 |
 ASTRAZENECA PLC$AZN | — | $89.9M | 456,031 |
 INVESCO QQQ TRUST, SERIES 1$QQQPUT | — | $86.6M | 150,000 |
 Cogent Biosciences, Inc.$COGT | — | $81.4M | 2,113,551 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Sofinnova Ventures Inc's 74 positions.
Showing top 10 of 74 holdings.
Sector Allocation
Healthcare
$2.0B
Full Holdings — Sofinnova Ventures Inc (Q1 2026)
All 74 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $NTRA | Natera, Inc. | $310.0M | 15.5% | +0% | 46.4 |
| 2 | — | iShares TR | $148.8M | — | NEW | — |
| 3 | — | SPDR Series Trust | $134.1M | — | NEW | — |
| 4 | $BMY | BRISTOL MYERS SQUIBB CO | $120.6M | 6.0% | +31% | 70.1 |
| 5 | $JAZZ | Jazz Pharmaceuticals plc | $113.1M | 5.7% | -38% | — |
| 6 | $VERA | Vera Therapeutics, Inc. | $112.4M | 5.6% | +0% | — |
| 7 | $UTHR | UNITED THERAPEUTICS Corp | $94.9M | 4.8% | +2% | 80.1 |
| 8 | $AZN | ASTRAZENECA PLC | $89.9M | 4.5% | -72% | — |
| 9 | $QQQPUT | INVESCO QQQ TRUST, SERIES 1 | $86.6M | — | NEW | — |
| 10 | $COGT | Cogent Biosciences, Inc. | $81.4M | 4.1% | +7% | — |
| 11 | — | iShares TR | $80.2M | — | NEW | — |
| 12 |  $RARE | Ultragenyx Pharmaceutical Inc. | $65.9M | 3.3% | +3677% | 31 |
| 13 |  $RAPP | Rapport Therapeutics, Inc. | $59.6M | 3.0% | +0% | — |
| 14 |  $INSM | INSMED Inc | $56.6M | 2.8% | +121% | 29.4 |
| 15 |  $ALC | ALCON INC | $55.0M | 2.8% | +120% | — |
| 16 |  $SUPN | SUPERNUS PHARMACEUTICALS, INC. | $49.3M | 2.5% | +73% | 45.3 |
| 17 | $UTHRPUT | UNITED THERAPEUTICS Corp | $47.6M | — | NEW | 80.1 |
| 18 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $44.2M | 2.2% | +12% | 74.1 |
| 19 |  $BIIB | BIOGEN INC. | $42.1M | 2.1% | NEW | 65.6 |
| 20 |  $CELC | Celcuity Inc. | $41.8M | 2.1% | +22% | — |
| 21 |  $BIOA | BioAge Labs, Inc. | $40.1M | 2.0% | +0% | 28.6 |
| 22 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $39.1M | 2.0% | +66% | 30.3 |
| 23 |  $AVBP | ArriVent BioPharma, Inc. | $39.1M | 2.0% | +0% | — |
| 24 |  $IDYA | IDEAYA Biosciences, Inc. | $37.7M | 1.9% | +28% | 10.5 |
| 25 |  $IMNM | Immunome Inc. | $37.2M | 1.9% | +5% | 5.8 |
| 26 |  $NKTR | NEKTAR THERAPEUTICS | $36.7M | 1.8% | +16% | 10.2 |
| 27 |  $AXSM | Axsome Therapeutics, Inc. | $36.0M | 1.8% | +1634% | 36.6 |
| 28 |  $IMTX | Immatics N.V. | $35.7M | 1.8% | +6% | — |
| 29 | $CELCPUT | Celcuity Inc. | $34.2M | — | NEW | — |
| 30 | $AXSMPUT | Axsome Therapeutics, Inc. | $33.8M | — | NEW | 36.6 |
| 31 |  $BBIO | BridgeBio Pharma, Inc. | $30.4M | 1.5% | -43% | 31.7 |
| 32 |  $DYN | Dyne Therapeutics, Inc. | $29.6M | 1.5% | -28% | — |
| 33 |  $INBX | Inhibrx Biosciences, Inc. | $27.3M | 1.4% | -11% | 3.1 |
| 34 |  $DXCM | DEXCOM INC | $24.7M | 1.2% | +4% | 77.9 |
| 35 |  $PHVS | Pharvaris N.V. | $23.1M | 1.2% | +10% | — |
| 36 |  $PFECALL | PFIZER INC | $22.5M | — | NEW | 69 |
| 37 |  $PRAX | Praxis Precision Medicines, Inc. | $20.5M | 1.0% | -49% | — |
| 38 |  $GMAB | GENMAB A/S | $20.2M | 1.0% | NEW | — |
| 39 |  $RCUS | Arcus Biosciences, Inc. | $19.9M | 1.0% | -16% | 12 |
| 40 |  $LQDAPUT | Liquidia Corp | $18.9M | — | NEW | 37.4 |
| 41 |  $XENE | Xenon Pharmaceuticals Inc. | $17.7M | 0.9% | +410% | 12.9 |
| 42 |  $SYK | STRYKER CORP | $14.6M | 0.7% | NEW | 69.8 |
| 43 |  $ANAB | ANAPTYSBIO, INC | $13.8M | 0.7% | -14% | 29.4 |
| 44 |  $ROIV | Roivant Sciences Ltd. | $13.2M | 0.7% | -35% | — |
| 45 |  $EWTX | Edgewise Therapeutics, Inc. | $12.2M | 0.6% | -12% | — |
| 46 |  $CMPX | Compass Therapeutics, Inc. | $10.9M | 0.5% | -39% | — |
| 47 |  $EXELPUT | EXELIXIS, INC. | $10.8M | — | NEW | 79.4 |
| 48 |  $ORIC | Oric Pharmaceuticals, Inc. | $8.6M | 0.4% | NEW | — |
| 49 |  $TNGX | Tango Therapeutics, Inc. | $8.3M | 0.4% | NEW | 26.9 |
| 50 |  $TYRA | Tyra Biosciences, Inc. | $7.8M | 0.4% | NEW | — |
| 51 |  $REPLCALL | Replimune Group, Inc. | $7.8M | — | NEW | — |
| 52 | $RARECALL | Ultragenyx Pharmaceutical Inc. | $7.3M | — | NEW | 31 |
| 53 |  $AXGN | Axogen, Inc. | $7.0M | 0.3% | NEW | 38 |
| 54 |  $DFTX | Definium Therapeutics, Inc. | $6.5M | 0.3% | NEW | — |
| 55 |  $CYTK | CYTOKINETICS INC | $6.0M | 0.3% | NEW | 28 |
| 56 |  $IRON | Disc Medicine, Inc. | $5.0M | 0.3% | -29% | — |
| 57 |  $MANE | Veradermics, Inc | $4.6M | 0.2% | NEW | — |
| 58 |  $HRMY | Harmony Biosciences Holdings, Inc. | $4.3M | 0.2% | NEW | 75.3 |
| 59 |  $PCVX | Vaxcyte, Inc. | $2.9M | 0.1% | NEW | — |
| 60 | $CMPXCALL | Compass Therapeutics, Inc. | $2.6M | — | NEW | — |
| 61 |  $MIRM | Mirum Pharmaceuticals, Inc. | $2.5M | 0.1% | +19% | 32.7 |
| 62 |  $NXTC | NextCure, Inc. | $2.4M | 0.1% | +0% | — |
| 63 |  $SVRA | Savara Inc | $2.0M | 0.1% | +20% | — |
| 64 |  $ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $1.9M | 0.1% | +20% | 26.7 |
| 65 |  $ACAD | ACADIA PHARMACEUTICALS INC | $1.7M | 0.1% | +20% | 69.8 |
| 66 |  $TENX | TENAX THERAPEUTICS, INC. | $1.7M | 0.1% | NEW | — |
| 67 |  $JBIO | Jade Biosciences, Inc. | $1.5M | 0.1% | +0% | — |
| 68 |  $WVE | Wave Life Sciences Ltd. | $1.4M | 0.1% | +20% | — |
| 69 |  $SEPN | Septerna, Inc. | $1.1M | 0.1% | NEW | 44.6 |
| 70 |  $OKUR | OnKure Therapeutics, Inc. | $586,638 | 0.0% | NEW | — |
| 71 |  $BOLT | Bolt Biotherapeutics, Inc. | $556,393 | 0.0% | +0% | — |
| 72 |  $SLNO | SOLENO THERAPEUTICS INC | $491,788 | 0.0% | +18% | 46.3 |
| 73 |  $IMA | ImageneBio, Inc. | $159,420 | 0.0% | +0% | 3.9 |
| 74 |  $ZYME | Zymeworks Inc. | $40,314 | 0.0% | NEW | 27.2 |
New Positions (29)
$QQQPUT INVESCO QQQ TRUST, SERIES 1$86.6M$UTHRPUT UNITED THERAPEUTICS Corp$47.6M$BIIB BIOGEN INC.$42.1M$CELCPUT Celcuity Inc.$34.2M$AXSMPUT Axsome Therapeutics, Inc.$33.8M$PFECALL PFIZER INC$22.5M$GMAB GENMAB A/S$20.2M$LQDAPUT Liquidia Corp$18.9M$SYK STRYKER CORP$14.6M$EXELPUT EXELIXIS, INC.$10.8M$ORIC Oric Pharmaceuticals, Inc.$8.6M$TNGX Tango Therapeutics, Inc.$8.3MExited Positions (15)
$VRTX VERTEX PHARMACEUTICALS INC / MA
$ABBV AbbVie Inc.
$ISRG INTUITIVE SURGICAL INC
$LLY ELI LILLY & Co
$RNA Avidity Biosciences, Inc.
$APGE Apogee Therapeutics, Inc.
$GKOS GLAUKOS Corp
$CNTA Centessa Pharmaceuticals plc
$GEHC GE HealthCare Technologies Inc.
$EXK ENDEAVOUR SILVER CORP
$AMLX Amylyx Pharmaceuticals, Inc.
$MASI MASIMO CORP
$QURE uniQure N.V.
$EVMN Evommune, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Sofinnova Ventures Inc including:
Track Sofinnova Ventures Inc's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Sofinnova Ventures Inc and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Sofinnova Ventures Inc
13F Pro is an AI hedge fund tracker and stock research platform. For Sofinnova Ventures Inc (SEC CIK: 1631134), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Sofinnova Ventures Inc's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.